|
||||||||||||||||||||||
|
|
Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer
Basic Trial Information
Summary The primary objective is to compare the objective response rate of AVE0005 (VEGF Trap) 4.0 mg/kg and 2.0 mg/kg intravenous (IV) every 2 weeks with historical control in patients with advanced ovarian epithelial (including fallopian tube and primary peritoneal) adenocarcinoma resistant to platinum and topotecan and/or liposomal doxorubicin. The secondary objectives are to further assess efficacy, safety, pharmacokinetics, immunogenicity, potential biological and pharmacogenomic markers of study drug activity, and health-related quality of life. Eligibility Criteria Inclusion Criteria:
Exclusion Criteria:
Trial Lead Organizations/Sponsors Sanofi-Aventis - US - Bridgewater Regeneron Pharmaceuticals
Link to the current ClinicalTrials.gov record. Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |